You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameMMP13 peptide (Hinge Region)See all MMP13 proteins and peptides ...
  • Protein descriptionSynthetic peptide MMP13. (Note: the amino acid sequence is proprietary) This peptide was used as an immunogen for ab39012 - MMP13 antibody - Hinge region.

    • Properties

  • Purity> 95 % by SDS-PAGE
  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: None
    Constituents: 0.001% Tween 20, 30mM HEPES, 2mM EDTA, 150mM Sodium chloride, pH 6.75
  • Concentration information loading...
  • Research Areas

    • Applications

    Our Abpromise guarantee covers the use of ab44853 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Notes
    ELISA
    WB
  • Application notesELISA: Use at an assay dependent dilution. WB: Use at an assay dependent dilution. This peptide can be used with studies using ab39012. Dilution optimised using Chromogenic detection. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.

    • Protein info

    • Alternative names
        CLG 3CLG3CLG3
        Collagenase 3Collagenase 3Collagenase3MANDP1Matrix metallopeptidase 13 (collagenase 3)Matrix Metalloproteinase 13Matrix Metalloproteinase 13Matrix metalloproteinase-13MMP 13MMP-13Mmp13MMP13_HUMAN
      see all
  • FunctionDegrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process.
  • Tissue specificitySeems to be specific to breast carcinomas.
  • Involvement in diseaseDefects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO) [MIM:602111]. A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age.
    Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1) [MIM:602111]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia.
  • Sequence similaritiesBelongs to the peptidase M10A family.
    Contains 4 hemopexin-like domains.
  • DomainThe conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
  • Cellular localizationSecreted > extracellular space > extracellular matrix.

    • Target information above from: UniProt accession P45452 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt

    References for MMP13 peptide (Hinge Region) (ab44853)

    ab44853 has not yet been referenced specifically in any publications.

    Publishing research using ab44853 ? Please let us know so that we can cite the reference in this datasheet

    Product Wall

    Submit an Abreview for ab44853 Submit a Question for ab44853

    There are currently no Abreviews or Questions for ab44853.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"